Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Magdy Abdelhamid, Kamal Al Ghalayini, Khaldoon Al-Humood, Bülent Altun, Mohammed Arafah, Feras Bader, Mohamed Ibrahim, Hani Sabbour, Ahmed Shawky Elserafy, Hadi Skouri, Mehmet Birhan Yilmaz
Although epidemiological data on heart failure (HF) with preserved ejection fraction (HFpEF) are scarce in the Middle East, North Africa and Turkey (MENAT) region, Lancet Global Burden of Disease estimated the prevalence of HF in the MENAT region in 2019 to be 0.78%, versus 0.71% globally. There is also a high incidence of HFpEF risk factors and co-morbidities in the region, including coronary artery disease, diabetes, obesity, hypertension, anaemia and chronic kidney disease. For instance, 14.5-16.2% of adults in the region reportedly have diabetes, versus 7...
October 2023: ESC Heart Failure
#22
JOURNAL ARTICLE
Paolo Gatti, Stefan Lind, Ingibjörg Kristjánsdóttir, Ava Azari, Gianluigi Savarese, Matteo Anselmino, Cecilia Linde, Fredrik Gadler
BACKGROUND: The left bundle branch block (LBBB) might be the first finding of cardiovascular diseases but also the prerequisite for cardiac resynchronization therapy (CRT) in heart failure (HF) with reduced ejection fraction (HFrEF). The prognosis for patients with LBBB and the implications of CRT in an unselected real-world setting are of great interest. METHODS: A central ECG database and national registers have been screened to identify patients with LBBB. Predictors of HF and use of CRT were identified with Cox models...
July 5, 2023: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
#23
REVIEW
H K Chopra, G S Wander, C K Ponde, Navin C Nanda, Dinesh Khullar, K Venugopal, Saumitra Ray, Tiny Nair, D S Rana, Vijay Kher, J P S Sawhney, R R Kasliwa, A Jabir, Rabin Chakraborty, Praveen Chandra, Sandeep Bansal, Viveka Kumar, A K Pancholia, Aditya Kapoor, Sunil Prakash, Anil Saxena, Vishal Rastogi, Vinod Sharma, Y K Arora, Arup Dasbiswas, Mohan Bhargava, Aparna Jaswal, K Bhargava, Mona Bhatia, A K Omar, N N Khanna, Rajiv Passey, Dilip Bhalla, I B Vijayalakshmi, A K Bhalla, Asha Moorthy, H S Isser, S S Mishra, S N Routray, Vivek Tandon, Ajay Sinha, Manish Bansal, Praveen Jain, Ramesh Hotchandani, Dharmendra Jain, V K Katyal, Sanjiv Gulati, Rohit Tandon, Shalini Jaggi, Blessy Sehgal, Vitull Gupta, Rahul Mehrotra, N C Krishnamani, S N Pathak, M S Yadav, Rajeev Chawla, Jyotirmoy Pal, Nandini Chatterjee, Shambo S Samajdar, N R Shastry
;Heart failure (HF) is a huge global public health task due to morbidity, mortality, disturbed quality of life, and major economic burden. It is an area of active research and newer treatment strategies are evolving. Recently angiotensin receptor-neprilysin inhibitor (ARNI), a class of drugs (the first agent in this class, Sacubitril-Valsartan), reduces cardiovascular mortality and morbidity in chronic HF patients with reduced left ventricular ejection fraction (LVEF). Positive therapeutic effects have led to a decrease in cardiovascular mortality and HF hospitalizations (HFH), with a favorable safety profile, and have been documented in several clinical studies with an unquestionable survival benefit with ARNI, Sacubitril-Valsartan...
February 2023: Journal of the Association of Physicians of India
#24
REVIEW
Said Nabil
Heart failure (HF), a type of cardiovascular disease (CVD), is a major cause of death globally and significantly burdens patients and the healthcare systems. Therefore, an improved treatment strategy is a necessity to reduce the mortality and morbidity rates and reduce its associated costs. Continuous updates in guidelines for the treatment of heart failure, especially for heart failure with reduced ejection fraction (HFrEF), have become evident in the last 5 years. An extensive literature search was conducted and the most recently published guideline recommendations for managing HFrEF in China, Canada, Europe, Portugal, Russia, and the United States were extracted...
October 2023: Current Problems in Cardiology
#25
RANDOMIZED CONTROLLED TRIAL
Nabil Naser, Azra Durak-Nalbantic, Nirvana Sabanovic-Bajramovic, Alen Karic
BACKGROUND: Heart failure remains one of the most prevalent clinical syndromes associated with significant morbidity and mortality. According to current guidelines, the prescription of a MRA is recommended to reduce the risk of HF hospitalization and death in all patients with symptomatic heart failure and no contraindications for this therapy. OBJECTIVE: The aim of our study was to determine the efficacy of eplerenone vs. spironolactone on left ventricular systolic function by measuring left ventricle ejection fraction (LVEF) in patients with chronic heart failure, especially their effect on preventing hospitalization, reducing mortality, and improving clinical status among patients with chronic HF...
April 2023: Medical Archives
#26
JOURNAL ARTICLE
Chern-En Chiang, Chung-Lieh Hung, Yen-Wen Wu, Tsung-Hsien Lin, Kwo-Chang Ueng, Shih-Hsien Sung, Cho-Kai Wu, Ting-Hsing Chao, Hung-Ju Lin, Yen-Hung Lin, Jin-Long Huang, Michael Yu Chih Chen, Po-Lin Lin, Tze-Fan Chao, Hao-Min Cheng, Ming-En Liu, Tzung-Dau Wang, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Wei-Hsian Yin, I-Chang Hsieh, Chun-Chieh Wang, Chen-Huan Chen, Pao-Hsien Chu, Shing-Jong Lin, San-Jou Yeh, Jiunn-Lee Lin, Juey-Jen Hwang, Huei-Fong Hung, Wen-Jone Chen, Charles Jia-Yin Hou
The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure...
May 2023: Acta Cardiologica Sinica
#27
Silvius Alexandru Pescariu, Raluca Șoșdean, Monica Nicoleta Mircea, Adina Ionac, Sorin Pescariu
Heart failure with reduced ejection fraction (HFrEF) is a chronic and debilitating disease, which requires extensive diagnostic and treatment resources in order to achieve an acceptable quality of life for the patient. While optimal medical treatment remains at the core of the disease's management, interventional cardiology also plays a very important role. However, in very rare situations, interventionists might find cases especially challenging due to the presence of venous anomalies, such as persistent left superior vena cava (PLSVC), anomalies that may go undiscovered during the patient's lifetime until venous cannulation is necessary...
April 18, 2023: Biomedicines
#28
JOURNAL ARTICLE
Yaar S Aga, Sabrina Abou Kamar, Jie Fen Chin, Victor J van den Berg, Mihai Strachinaru, Daniel Bowen, Rene Frowijn, Martijn K Akkerhuis, Alina A Constantinescu, Victor Umans, Marcel L Geleijnse, Eric Boersma, Jasper J Brugts, Isabella Kardys, Bas M van Dalen
AIMS: In a large proportion of heart failure with reduced ejection fraction (HFrEF) patients, echocardiographic estimation of left atrial pressure (LAP) is not possible when the ratio of the peak early left ventricular filling velocity over the late filling velocity (E/A ratio) is not available, which may occur due to several potential causes. Left atrial reservoir strain (LASr) is correlated with LV filling pressures and may serve as an alternative parameter in these patients. The aim of this study was to determine whether LASr can be used to estimate LAP in HFrEF patients in whom E/A ratio is not available...
May 8, 2023: ESC Heart Failure
#29
JOURNAL ARTICLE
Albert S Yu, Katherine J Pak, Hui Zhou, Sally F Shaw, Jiaxiao Shi, Benjamin I Broder, John J Sim
RATIONALE & OBJECTIVE: Heart failure and chronic kidney disease (CKD) frequently coexist reflective of the strong interplay between these organ systems. A better understanding of the prevalence of different types of heart failure (preserved and reduced ejection fraction) and their subsequent mortality risks among advanced CKD patients would provide important epidemiologic insights and may pave the way for more focused and proactive management strategies. STUDY DESIGN: Retrospective cohort study...
May 2023: Kidney medicine
#30
JOURNAL ARTICLE
Giuseppe Caminiti, Barbara Sposato, Maurizio Volterrani
The introduction of multiple new pharmacological agents over the past three decades in the field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of mortality and hospitalizations, and consequently, the prevalence of HFrEF has increased, and up to 10% of patients progress to more advanced stages, characterized by high rates of mortality and hospitalizations and poor quality of life. Vericiguat, a novel oral soluble guanylate cyclase stimulator, has proved effective in patients with HFrEF who had recently been hospitalized or had received intravenous diuretic therapy...
May 2023: European Heart Journal Supplements: Journal of the European Society of Cardiology
#31
REVIEW
Alexandre Rodrigues, Alexandre Gonçalves, Juliana Morais, Ricardo Araujo, Inês Falcão-Pires
Heart failure (HF) is a debilitating disease with a significant clinical and economic impact worldwide. Multiple factors seem to increase the risk of developing HF, such as hypertension, obesity and diabetes. Since chronic inflammation plays a significant role in HF pathophysiology and gut dysbiosis is associated with low-grade chronic inflammation, the risk of cardiovascular diseases is likely modulated by the gut microbiome (GM). Considerable progress has been made in HF management. However, there is a need to find new strategies to reduce mortality and increase the quality of life, mainly of HFpEF patients, since its prevalence continues to rise...
February 28, 2023: Nutrients
#32
JOURNAL ARTICLE
Ahmad Mroué, Stéphane Roueff, Isabella Vanorio-Vega, Hélène Lazareth, Oksana Kovalska, Adrien Flahault, Philippe Tuppin, Eric Thervet, Marie-Christine Iliou
PURPOSE: Chronic kidney disease (CKD) is common in heart failure (HF). Chronic kidney disease often worsens the prognosis and impairs the management of patients with HF. Chronic kidney disease is frequently accompanied by sarcopenia, which limits the benefits of cardiac rehabilitation (CR). The aim of this study was to evaluate the impact of CR on cardiorespiratory fitness in HF patients with reduced ejection fraction (HFrEF) according to the CKD stage. METHODS: We conducted a retrospective study including 567 consecutive patients with HFrEF, who underwent a 4-wk CR program, and who were evaluated by cardiorespiratory exercise test before and after the program...
March 10, 2023: Journal of Cardiopulmonary Rehabilitation and Prevention
#33
JOURNAL ARTICLE
Mariano A Giorgi, Carlos P Boissonnet, Paula Soledad Luque, Jimena Piastrella, Carlos Porley, Fernanda Ditata, Sergio Volman
BACKGROUND: Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor-ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with enalapril. It proved to be a cost-effective treatment in many countries with stable economies. In Argentina, a country with chronic financial instability and a fragmented health care system, the estimation of its cost-effectiveness requires to consider local financial data...
February 18, 2023: Health Economics Review
#34
JOURNAL ARTICLE
Aaron Plosker, WIlliam H Frishman
Heart failure (HF) affects approximately 6 million Americans and is projected to increase in prevalence as the population ages. While progress has been made in the treatment of heart failure with reduced ejection fraction (HFrEF), treatments for heart failure with preserved ejection fraction (HFpEF) are few and far between. Since HFpEF makes up half of all heart failure cases, its management may be the biggest unmet need in cardiology. Results from the recent EMPEROR-Preserved trial are encouraging. After 26 months, patients with HFpEF who used the sodium-glucose co-transporter 2 inhibitor empagliflozin had a lower risk of hospitalization for HF than patients taking a placebo...
December 28, 2022: Cardiology in Review
#35
JOURNAL ARTICLE
Chun Ka Wong, Ka Chun Un, Mi Zhou, Yangyang Cheng, Yuk Ming Lau, Puigi Catherine Shea, Hin Wai Lui, Ming Liang Zuo, Li Xue Yin, Esther W Chan, Ian C K Wong, Simon Wai Ching Sin, Pauline Pui Ning Yeung, Hao Chen, Sandi Wibowo, Tong Li Nikki Wei, Sze Ming Lee, Augustine Chow, Raymond Cheuk Fung Tong, Jojo Hai, Frankie Chor Cheung Tam, Chung Wah Siu
AIMS: Underutilization of guideline-directed heart failure with reduced ejection fraction (HFrEF) medications contributes to poor outcomes. METHODS AND RESULTS: A pilot study to evaluate the safety and efficacy of a home-based remote monitoring system for HFrEF management was performed. The system included wearable armband monitors paired with the smartphone application. An HFrEF medication titration algorithm was used to adjust medication daily. The primary endpoint was HFrEF medication utilization at 120 days...
June 2022: European heart journal. Digital health
#36
REVIEW
Maria Velliou, Effie Polyzogopoulou, Ioannis Ventoulis, John Parissis
INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of oral antiglycemic agents that have emerged as a new therapeutic strategy for heart failure (HF) with reduced ejection fraction (HFrEF) and, potentially, for HF with preserved ejection fraction (HFpEF). AREAS COVERED: Ongoing efforts to clarify the exact mechanisms of action of SGLT2 inhibitors (SGLT2i) reveal that glycosuria and osmotic diuresis, resulting from the blockade of renal receptors, is not the sole pathophysiological mechanism...
February 2023: Expert Review of Clinical Pharmacology
#37
Pooja Roy, Zahin Islam Rafa, Harshita Agrawal, Soumyadipto B Arko
A relatively new yet critical phenomenon of bradycardia, renal failure, atrioventricular (AV) blockade, shock, and hyperkalemia (BRASH) syndrome is hypothesized to happen in patients who take atrioventricular nodal blocking (AVNB) agents and have underlying renal insufficiency. In our case, a 67-year-old female with an extensive medical history presented to the emergency room with chief complaints of decreased appetite, nausea, vomiting, fatigue, and left-sided atypical chest pain for the past two weeks. The patient was taking losartan potassium 50 mg daily in addition to carvedilol 6...
December 2022: Curēus
#38
REVIEW
Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone
One of the most relevant and differentiating aspects provided by the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure is the retraction of the historical stepped and vertical pharmacological treatment scheme for heart failure with reduced ejection fraction (HFrEF). Subsequently, it was replaced by an updated algorithm that places four therapeutic families in the same initial horizontal step with an equally high degree of recommendation (class I)...
2023: Drugs in Context
#39
REVIEW
Lorenzo Pistelli, Francesca Parisi, Michele Correale, Federica Cocuzza, Francesca Campanella, Tommaso de Ferrari, Pasquale Crea, Rosalba De Sarro, Olga La Cognata, Simona Ceratti, Tonino Recupero, Gaetano Ruocco, Alberto Palazzuoli, Egidio Imbalzano, Giuseppe Dattilo
Heart failure (HF) is a complex, multifactorial, progressive clinical condition affecting 64.3 million people worldwide, with a strong impact in terms of morbidity, mortality and public health costs. In the last 50 years, along with a better understanding of HF physiopathology and in agreement with the four main models of HF, many therapeutic options have been developed. Recently, the European Society of Cardiology (ESC) HF guidelines enthusiastically introduced inhibitors of the sodium-glucose cotransporter (SGLT2i) as first line therapy for HF with reduced ejection fraction (HFrEF) in order to reduce hospitalizations and mortality...
January 3, 2023: Journal of Clinical Medicine
#40
REVIEW
Mauro Riccardi, Antonio Maria Sammartino, Massimo Piepoli, Marianna Adamo, Matteo Pagnesi, Giuseppe Rosano, Marco Metra, Stephan von Haehling, Daniela Tomasoni
In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst verciguat is becoming available across several countries, omecamtiv mecarbil is waiting to be released for clinical use. Concurrent use of potassium-lowering agents may counteract hyperkalaemia and facilitate renin-angiotensin-aldosterone system inhibitor implementations. The results of the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) trial were confirmed by the Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER) trial, and we now have, for the first time, evidence for treatment of also patients with HF with preserved ejection fraction...
December 2022: ESC Heart Failure
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
